Rockefeller Capital Management
CSTL icon

Rockefeller Capital Management’s Castle Biosciences CSTL Stock Holding History

Rockefeller Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6K Buy
433
+346
+398% +$11.3K ﹤0.01% 3967
2025
Q4 		$3.38K Buy
+87
New +$2.81K ﹤0.01% 4184
2023
Q1 		– Sell
-4,294
Closed -$101K – 2378
2022
Q4 		$101K Buy
4,294
+154
+4% +$3.57K ﹤0.01% 2018
2022
Q3 		$107K Buy
4,140
+3,940
+1,970% +$110K ﹤0.01% 1950
2022
Q2 		$4K Sell
200
-22
-10% -$511 ﹤0.01% 3519
2022
Q1 		$9K Buy
222
+22
+11% +$909 ﹤0.01% 3097
2021
Q4 		$8K Hold
200
– – ﹤0.01% 3071
2021
Q3 		$13K Hold
200
– – ﹤0.01% 2764
2021
Q2 		$14K Sell
200
-1
-0.5% -$66 ﹤0.01% 2630
2021
Q1 		$13K Buy
+201
New +$15.1K ﹤0.01% 2470

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rockefeller Capital Management's CSTL Position: Q1 2026 in Review

Rockefeller Capital Management increased its Castle Biosciences (CSTL) stake by 398% in Q1 2026, buying an estimated $11.3K and bringing the position to 433 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3967.

Rockefeller Capital Management first reported a position in CSTL in Q1 2021 and has held it in 10 quarters since. The position peaked at $107K in Q3 2022. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Rockefeller Capital Management held 433 shares of Castle Biosciences worth $10.6K as of Q1 2026.
  • Rockefeller Capital Management bought 346 Castle Biosciences shares in Q1 2026, an estimated $11.3K.
  • Castle Biosciences made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #3967 holding.
  • Rockefeller Capital Management first reported a position in Castle Biosciences in Q1 2021 and has held it in 10 quarters since.
  • Rockefeller Capital Management's Castle Biosciences position peaked at $107K in Q3 2022.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.